A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates | Science Advances
Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16 | Scientific Reports
Microorganisms | Free Full-Text | Persistence of Coxsackievirus B4 in Pancreatic β Cells Disturbs Insulin Maturation, Pattern of Cellular Proteins, and DNA Methylation | HTML
Frontiers | How Does Thymus Infection by Coxsackievirus Contribute to the Pathogenesis of Type 1 Diabetes?
Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design | Journal of Virology
A Common Virus May Be Linked to Heart Problems in Fetuses | Live Science
Coxsackievirus B3 replication and pathogenesis | Future Microbiology
Structure-Function Analysis of the Coxsackievirus Protein 3A - Journal of Biological Chemistry
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer: Molecular Therapy - Oncolytics
Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis | ACS Infectious Diseases
Wells' Syndrome Associated with Coxsackievirus A6 Infection | HTML | Acta Dermato-Venereologica
Viruses | Free Full-Text | Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms | HTML
PDF) Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10
Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design | Journal of Virology
Cum se manifestă infecţia cu virusurile Coxsackie
Molecular basis of Coxsackievirus A10 entry using the two-in-one attachment and uncoating receptor KRM1 | PNAS
Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3 - ScienceDirect
Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway | Scientific Reports
Download PDF | Coxsackie A16 Virus-associated Atypical Hand-foot-and-mouth Disease
Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway | Scientific Reports
Antiviral Activity of Oroxylin A against Coxsackievirus B3 Alleviates Virus-Induced Acute Pancreatic Damage in Mice | PLOS ONE
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma: Molecular Therapy - Oncolytics
Frontiers | Neonatal Murine Model of Coxsackievirus A2 Infection for the Evaluation of Antiviral Therapeutics and Vaccination
Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients | PNAS
